Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 109-126 , October 2010

Nerve Growth Factor in Rheumatic Diseases

  • Matthias F. Seidel, MD

      Affiliations

    • Medizinische Klinik und Poliklink I, Rheumatology, Bonn, Germany
    • Corresponding Author InformationAddress reprint requests to Matthias F. Seidel, MD, Medizinische Klinik und Poliklink I, Rheumatology, Wilhelmstraβe 35-37, D-53111 Bonn, Germany
    • ,
  • Marjeta Herguijuela, MD

      Affiliations

    • Seidel-Klinik, Bad Bellingen, Germany
    • ,
  • Randolf Forkert, MD

      Affiliations

    • Johanniter Krankenhaus, Bonn, Germany
    • ,
  • Uwe Otten, MD

      Affiliations

    • Universität Basel, Institut für Physiologie, Basel, Switzerland

References 

  1. Kidd BL, Mapp PI, Gibson SL, Polak JM, O'Higgins F, Buckland-Wrigth JC, et al. A neurogenic mechanism for symmetrical arthritis. Lancet. 1989;2(8672):1128–1130
  2. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Ann Rev Neurosci. 2006;29:507–538
  3. Thompson M, Bywaters EGL. Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis. 1962;21:370–377
  4. Seidel M, Tsalik J, Vetter H, Müller W. Substance P in rheumatic disease. Curr Rheum Rev. 2007;1(3):17–30
  5. Klein R. Role of neurotrophins in mouse neuronal devolopment. FASEB J. 1994;8(10):738–744
  6. Amann R, Sirinathsinghji DJS, Donnerer J, Lieberman I, Schuligoi R. Stimulation by nerve growth factor of neuropeptide synthesis in the adult rat in vivo: bilateral response to unilateral intraplantar injections. Neurosci Lett. 1996;203:171–174
  7. Lindsay RM, Harmer AJ. Nerve growth factor regulates expression of neuropeptides genes in adult sensory neurons. Nature. 1989;337:362–364
  8. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. The expanding role of nerve growth factor: from the neurotrophic activity to immunological diseases. Allergy. 1997;52(9):883–894
  9. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989;341(6238):149–152
  10. Ernfors P, Ibáñez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarity to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA. 1990;87(14):5454–5458
  11. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990;247(4949 Pt. 1):1446–1451
  12. Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron. 1991;7(5):857–866
  13. Hallbook F, Ibanez CF, Persson H. Evolutionary studies of nerve growth factor family reveal a new member abundantly expressed in Xenopus ovary. Neuron. 1991;6:845–858
  14. Götz R, Köster R, Winkler C, Raulf F, Lottspeich F, Schartl M, et al. Neurotrophin-6 is a new member of the nerve growth factor family. Nature. 1994;372(6503):266–269
  15. Jelsma JN, Aguayo AJ. Trophic factors. Curr Opinion Neurobiol. 1994;4(5):717–725
  16. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci. 1993;13(7):2739–2748
  17. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors: from molecule to man. Trends Neurosci. 1994;17(5):182–190
  18. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Ann Rev Neurosc. 2001;24:1217–1281
  19. Adler R, Landa KB, Manthorpe M, Varon S. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science. 1979;204:1434–1436
  20. Yamamori T, Fukada K, Aebersold R, Korsching S, Fann MJ, Patterson PH. The cholinergic neuronal differentiation factor from heart cells is identical to leukemia inhibitory factor. Science. 1989;246(4936):1412–1416
  21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20
  22. Varon S, Nomura J, Shooter EM. Reversible dissociation of the mouse nerve growth factor protein into different subunits. Biochem. 1968;7:1296–1303
  23. Bresnahan PA, Leduc R, Thomas L, Thorner J, Gibson HL, Brake AJ, et al. Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-β-NGF in vivo. J Cell Biol. 1990;111:2851–2859
  24. Dicou E, Lee J, Brachet P. Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat. Proc Natl Acad Sci USA. 1986;83:7084–7088
  25. Arnett MG, Ryals JM, Wright DE. pro-NGF, sortilin, and p75(NTR): potential mediators of injury-induced apoptosis in the mouse dorsal root ganglion. Brain Res. 2007;1183:32–42
  26. Lakshmanan J, Burns C, Smith RA. Molecular forms of nerve growth factor in mouse submaxillary glands. Biochem Biophys Res Commun. 1988;152(3):1008–1014
  27. Reinshagen M, Geerling I, Eysselein VE, Adler G, Huff KR, Moore GP, et al. Commercial recombinant human beta-nerve growth factor and adult rat dorsal root ganglia contain an identical molecular species of nerve growth factor prohormone. J Neurochem. 2000;74(5):2127–2133
  28. Yiangou Y, Facer P, Sinicropi DV, Boucher TJ, Bennett DL, McMahon SB, et al. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. JPNS. 2002;7(3):190–197
  29. Darling TLJ, Petrides PE, Beguin P, Frey P, Shooter EM, Selby M, et al. The biosynthesis and processing of proteins in the mouse 7S nerve growth factor complex. Cold Spring Harbor Symp Quant Biol. 1983;48(Pt. 1):427–434
  30. Selby MJ, Edwards R, Sharp F, Rutter WJ. Mouse nerve growth factor gene: structur and expression. Mol Cell Biol. 1987;7(9):3057–3064
  31. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci. 2001;18(2):210–220
  32. Server AC, Shooter EM. Nerve growth factor. Adv Protein Chem. 1977;31:339–409
  33. Ullrich A, Gray A, Berman C, Dull TJ. Human β-nerve growth factor gene sequence highly homologous to that of mouse. Nature. 1983;303:821–825
  34. Scott J, Selby M, Urdea M, Quiroga M, Bell GI, Rutter WJ. Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor. Nature. 1983;302(5908):538–540
  35. Varon S, Shooter EM. The nerve growth factor proteins of the mouse submaxillary gland. In:  Bowman RE,  Datta SP editor. Biochemistry of brain and behaviour. New York, NY: Plenum; 1970;p. 41–64
  36. Greene LA, Shooter EM, Varon S. Subunit interaction and enzymatic activity of mouse 7S nerve growth factor. Biochemistry. 1969;8(9):3735–3741
  37. Evans BA, Richards RI. Genes for the α and γ subunits of mouse nerve growth factor are contiguous. EMBO J. 1985;4(1):133–138
  38. Thomas KA, Baglan NC, Bradshaw RA. The amino acid sequence of the γ-subunit of mouse submaxillary gland 7S nerve growth factor. J Biol Chem. 1981;256(17):9156–9166
  39. Ullrich A, Gray A, Wood WI, Hayflick J, Seeburg P. Isolation of a cDNA clone coding for the gamma-subunit of mouse nerve growth factor using a high-stringency selection procedure. DNA. 1984;3(5):387–392
  40. Isackson PJ, Brandshaw RA. The α-subunit of mouse 7S nerve growth factor is an inactive serine protease. J Biol Chem. 1984;259(9):5380–5383
  41. Thomas KA, Silverman RE, Jeng I, Baglan NC, Bradshaw RA. Electrophoretic heterogeneity and polypeptide chain structure of the γ-subunit of mouse submaxillary 7S nerve growth factor. J Biol Chem. 1981;256(17):9147–9155
  42. Hennigan A, O'Callaghan RM, Kelly AM. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans. 2007;35(2):424–427
  43. Barker PA, Murphy RA. The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins. Mol Cell Biochem. 1992;110(1):1–15
  44. Mallett S, Barclay AN. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today. 1991;1287:220–223
  45. Barbacid M. Nerve growth factor: a tale of 2 receptors. Oncogene. 1993;8(8):2033–2042
  46. Green SH, Rydel RE, Connoly JL, Greene LA. PC12 mutants that possess low- but not not high-affinity nerve growth factor receptors neither respond to nor internalise nerve growth factor. J Cell Biol. 1986;102(3):830–843
  47. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci. 1992;15:323–331
  48. Holtzman DM, Kilbridge J, Li Y, Cunningham ET, Lenn NJ, Clary DO, et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J Neurosci. 1995;15(2):1567–1576
  49. Ehrhard PB, Erb P, Graumann U, Otten U. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase trk in activated CD4-positive T-cell clones. Proc Natl Acad Sci USA. 1993;90:10984–10988
  50. Ehrhard PB, Erb P, Graumann U, Schmutz B, Otten U. Expression of functional trk tyrosine kinase receptors after T cell activation. J Immunol. 1994;152(6):2705–2709
  51. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA. 1989;86:10059–10063
  52. Ehrhard PB, Ganter U, Bauer J, Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA. 1993;90:5423–5427
  53. Horigome K, Pryor JC, Bullock ED, Johnson EM. Mediator release from mast cells by nerve growth factor, neurotrophin specifity and receptor mediation. J Biol Chem. 1993;268(20):14881–14887
  54. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low affinity NGF receptor. Nature. 1991;350(6320):678–683
  55. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–160
  56. Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189–197
  57. Loeb DM, Maragos J, Martin-Zanca D, Chao MV, Parada LF, Greene LA. The trk proto-oncogene rescues NGF responsiveness in mutant NGF-nonresponsive PC12 cell lines. Cell. 1991;66(5):961–966
  58. Ip NY, Stitt TN, Tapley P, Klein R, Glass DJ, Fandl J, et al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron. 1993;10(2):137–149
  59. Lamballe F, Klein R, Barbacid M. TrkC, a new member of the trk family of tyrosin protein kinases, is a receptor for neurotrophin-3. Cell. 1991;66(5):967–979
  60. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science. 1991;252(5005):554–558
  61. Barker PA, Shooter EM. Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to trkA on PC12 cells. Neuron. 1994;13(1):203–215
  62. Hantzopoulos PA, Suri C, Glass DJ, Goldfarb MP, Yancopoulos GD. The low affinity NGF receptor, p75, can collaborate with each of the trks to potentiate functional responses to the neurotrophins. Neuron. 1994;13(1):187–201
  63. Mahadeo D, Kaplan L, Chao MV, Hempstead BL. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding (Implications for multi-subunit polypeptide receptors). J Biol Chem. 1994;269(9):6884–6891
  64. Verdi JM, Birren SJ, Ibáñez CF, Persson H, Kaplan DR, Benedetti M, et al. p75LNGFR regulates trk signal transduction and NGF-induced neuronal differentiation in MAH cells. Neuron. 1994;12(4):733–745
  65. Hempstead BL, Schleifer LS, Chao MV. Expression of functional nerve growth factor receptors after gene transfer. Science. 1989;243(4889):373–376
  66. Barker PA, Barbee G, Misko TP, Shooter EM. The low affinity receptor, p75LNTR, is palmitoylated by thioester formation through cysteine 279. J Biol Chem. 1994;269(48):30645–30650
  67. Barker PA. p75NTR: a study in contrasts. Cell Death Differ. 1998;5(5):346–356
  68. Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J. 1999;18:616–622
  69. MacPhee IM, Barker PA. Brain-derived neurotrophic factor binding to the p75 neurotrophin receptor reduces TrkA signalling while increasing serine phosphorylation in the TrkA intracellular domain. J Biol Chem. 1997;272(38):23547–23551
  70. Martinez-Lavin M, Solano C. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain. Medical Hypoth. 2009;72(1):64–66
  71. Lewin GR, Ritter AM, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci. 1993;13(5):2136–2148
  72. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci. 1994;6:1903–1912
  73. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994;36:244–246
  74. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neurosci. 1992;49(3):693–698
  75. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62(2):327–331
  76. Davis BM, Albers KM, Seroogy KB, Katz DM. Overexpression of nerve growth factor in transgenic mice induces novel sympathetic projections to primary sensory neurons. J Comp Neurol. 1994;349(3):464–474
  77. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci. 1993;16(9):353–359
  78. Tria MA, Fusco M, Vantini G, Mariot R. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol. 1994;127(2):178–183
  79. Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain. 2003;104:241–247
  80. Davis BM, Lewin GR, Mendell LM, Jones ME, Albers KM. Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience. 1993;56(4):789–792
  81. Mamidipudi V, Wooten MW. Dual role for p75NTR signaling in survival and cell death: can intracellular mediators provide an explanation?. J Neurosci Res. 2002;68:373–384
  82. Szeberényi J. Gene activation pathways of nerve growth factor signaling: a minireview. Neurobiology. 1996;4:1–11
  83. Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, et al. How are the regulators regulated? (The search for mechanisms that impose specificity on induction of cell death and NF-κB activation by members of the TNF/NGF receptor family). Arthritis Res. 2002;4(3):S189–S196
  84. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokata T. Cytokines: coordinators of immune and inflammatory responses. Ann Rev Biochem. 1990;59:783–836
  85. Hartung HP, Schäfer B, Heininger K, Toyka KV. Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes. Brain Res. 1989;489(1):113–119
  86. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature. 1990;346(6281):274–276
  87. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol. 1992;40(2-3):197–210
  88. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolisaccharide or a neurotropic virus. Proc Natl Acad Sci USA. 1989;86(16):6348–6352
  89. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491(2):394–397
  90. Gadient RA, Cron KC, Otten U. Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci Lett. 1990;117(3):335–340
  91. Hattori A, Tanaka E, Murase K, Ishida N, Chatani Y, Tsujimoto M, et al. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J Biol Chem. 1993;268(4):2577–2582
  92. Aloe L, Manni L, Sebastiani G, Tuveri MA. Nerve growth factor in the synovia of patients with rheumatoid arthritis: correlation with TNF-α and IL-1β and possible functional significance. Clin Exp Rheumatol. 1999;17:632–633
  93. Manni L, Aloe L. Role of IL-1β and TNF-β in the regulation of NGF in experimentally induced arthritis in mice. Rheumatol Int. 1998;18:97–102
  94. Manni L, Lundeberg T, Fiorito S, Bonini S, Vigneti E, Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-α, interleukin-1β and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheum. 2003;21:617–624
  95. Akira S, Taga T, Kishimoto T. Inerleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78
  96. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989;19(4):689–694
  97. Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Med Inflamm. 1998;7:347–353
  98. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 1990;33(5):644–649
  99. Ehrhard PB, Ganter U, Bauer J, Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA. 1993;90:5423–5427
  100. Aloe L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res. 1977;133(2):358–366
  101. Manning PT, Russell JH, Simmons B, Johnson EM. Protection from guanethidine-induced neuronal destruction by nerve growth factor: effect of NGF on immune function. Brain Res. 1985;340(1):61–69
  102. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA. 1989;86:10059–10063
  103. Thorpe LW, Perez-Polo JR. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J Neurosci Res. 1987;18(1):134–139
  104. Lambiase A, Bracci-Laudiero L, Bonini S, Bonini S, Starace G, D‘Elios MM, et al. Human CD4+ T cell clones produce and release nerve growth factor and express high affinity nerve growth factor receptors. J Allergy Clin Immunol. 1997;100:408–414
  105. Gee AP, Boyle MD, Munger KL, Lawman MJP, Young M. Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA. 1983;80(23):7215–7218
  106. Otten U, Baumann JB, Girard J. Nerve growth factor induces plasma extravasation in rat skin. Eur J Pharmacol. 1984;106(1):199–201
  107. Aloe L, Tuveri MA, Levi-Montalcini R. Nerve growth factor and distribution of mast cells in the synovium of adult rats. Clin Exp Rheumatol. 1992;10:203–204
  108. Aloe L, Skaper SD, Leon A, Levi-Montalcini R. Nerve growth factor and autoimmune diseases. Autoimmunity. 1994;19:141–150
  109. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain. 2005;116(1-2):8–16
  110. Gigante A, Bevilacqua C, Pagnotta A, Manzotti S, Toesca A, Greco F. Expression of NGF (TrkA and p75 in human cartilage). Eur J Histochem. 2003;47(4):339–344
  111. Iannone F, De Bari C, Dell'Accio F, Covelli M, Patella V, Lo Bianco G, et al. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology. 2002;41:1413–1418
  112. Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, Lazarovici P, et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB. 2002;16(10):1307–1309
  113. Emanueli C, Salis MB, Pinna A, Graiani G, Manni L, Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimb. Circulation. 2002;106:2257–2262
  114. Turrini P, Gaetano C, Antonelli A, Capogrossi MC, Aloe L. Nerve growth factor induces angiogenic activity in a mouse model of hindlimb ischemia. Neurosci Lett. 2002;323(2):109–112
  115. Koizumi S, Contreras ML, Matsuda Y, Hama T. K-252a: a specific inhibitor of the action of nerve growth factor on PC12 cells. J Neurosci. 1988;8(2):715–721
  116. Raychaudhuri SP, Sanyal M, Weltman H, Kundu-Raychaudhuri SK. A high-affinity nerve growth factor receptor blocker improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol. 2004;123(3):812–819
  117. Cattaneo A, Capsoni S, Margotti E, Righi M, Kontsekova E, Pavlik P, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci. 1999;19(22):9687–9697
  118. Owolabi JB, Rizkalla G, Tehim A, Ross GM, Riopelle RJ, Kamboj R, et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther. 1999;289(3):1271–1276
  119. Dostaler SM, Ross GM, Myers SM, Weaver DF, Ananthanarayanan V, Riopelle RJ. Characterization of a distinctive motif of the low molecular weight neurotrophin receptor that modulates NGF-mediated neurite outgrowth. Eur J Neurosci. 1996;8(5):870–879
  120. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci. 1994;6:1903–1912
  121. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62(2):327–331
  122. McMahon SB, Bennett DLH, Priestly JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by trkA-IgG fusion molecule. Nat Med. 1995;1(8):774–780
  123. Belliveau DJ, Krivko I, Kohn J, Lachance C, Pozniak C, Rusakov D, et al. NGF and Neurotrophin-3 both activate trkA on sympathetic neurons but differentially regulate survival and neuritogenesis. J Cell Biol. 1997;136(2):375–388
  124. Cordon-Cardo C, Tapley P, Jing SQ, Nanduri V, O‘Rourke E, Lamballe F, et al. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell. 1991;66(1):173–183
  125. Mischel PS, Smith SG, Vining ER, Valletta JS, Mobley WC, Reichardt LF. The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through trkA. J Biol Chem. 2001;276(14):11294–11301
  126. Karchewski LA, Gratto KA, Wetmore C, Verge VMK. Dynamic patterns of BDNF expression in injured sensory neurons: differential modulation by NGF and NT-3. Eur J Neurosci. 2002;16(8):1449–1462
  127. Gratto KA, Verge VMK. Neurotrophin-3 down-regulates trkA mRNA, NGF high-affinity binding sites, and associated phenotype in adult DRG neurons. Eur J Neurosci. 2003;18:1535–1548
  128. Lane NE, Schnitzer TJ, Smit MD, Brown MT. Efficacy and safety of PF04383119 in treating moderate to severe pain due to osteoarthritis (OA). Ann Rheum Dis. 2008;67(Suppl II):237
  129. Aloe L, Skaper SD, Leon A, Levi-Montalcini R. Nerve growth factor and autoimmune diseases. Autoimmunity. 1994;19:141–150
  130. Aloe L, Tuveri MA, Levi-Montalcini R. Studies on the carrageenan-induced arthritis in adult rats: presence of nerve growth factor and role of sympathetic innervation. Rheumatol Int. 1992;12:213–216
  131. Langevitz P, Buskila D, Gladman DD. Psoriatic arthritis precipitated by physical trauma. J Rheumatol. 1990;17(5):695–697
  132. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992;49(3):693–698
  133. Nguyen CB, Harris L, Szönyi É, Baughman SA, Hale VG, Dybdal NO, et al. Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys. Drug Metabol Dis. 2000;28(5):598–607
  134. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum. 1997;40(4):598–609
  135. Fitzgerald M. Arthritis and the nervous system. TINS. 1989;12(3):86–87
  136. Malone DG, Wilder RL, Saavedra-Delgado AMS, Metcalfe DD. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by anti-inflammatory therapy. Arthr Rheum. 1987;30(2):130–137
  137. Zvaifler NJ. A retrospective analysis of the pathogenesis of rheumatoid arthritis. Rev Rhum. 1996;63(11):791–796
  138. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 1998;41(6):951–962
  139. Takei Y, Laskey R. Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol Med. 2008;14(9):381–388
  140. Aloe L, Bracci-Laudiero L, Alleva E, Lambiase A, Micera A, Tirassa P. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc Natl Acad Sci USA. 1994;25(91,22):10440–10444
  141. Baker GH. Life events before the onset of rheumatoid arthritis. Psychother Psychosom. 1982;38(1):173–177
  142. Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum. 1992;35(3):351–355
  143. Halliday DA, Zettler C, Rush RA, Scicchitano R, McNeil JD. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res. 1998;23(6):919–922
  144. Del Porto F, Aloe L, Lagana B, Triaca V, Nofroni I, D'Amelio R. Nerve growth factor and brain-derived neurothrophic factor levels in patients with rheumatic arthritis treated with TNF-alpha-blockers. Ann NY Acad Sci. 2006;1069:438–443
  145. Pozza M, Guerra M, Manzini E, Calzà L. A histochemical study of the rheumatoid synovium: focus on nitric oxide, nerve growth factor high affinity receptor, and innervation. J Rheumatol. 2000;27:1121–1127
  146. Dicou E, Masson C, Jabbour W, Nerriere V. Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients. Neuroreport. 1993;5:321–324
  147. Falcini F, Matucci Cerinic M, Lombardi A, Generini S, Pignone A, Tirassa P, et al. Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. Ann Rheum Dis. 1996;55:745–748
  148. Pincelli C, Haake AR, Benassi L, Grassilli E, Magnoni C, Ottani D, et al. Autocrine nerve growth factor protects human keratinocytes from apoptosis through its high affinity receptor (TRK): a role for BCL-2. J Invest Dermatol. 1997;109(6):757–764
  149. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol. 2000;43(4):595–604
  150. Boehncke WH, Zollner TM, Dressel D, Kaufmann R. Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol. 1997;24(1):1–7
  151. Raychaudhuri SP, Dutt S, Raychaudhuri SK, Sanyal M, Farber EM. Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br J Dermatol. 2001;144(5):931–939
  152. Langevitz P, Buskila D, Gladman DD. Psoriatic arthritis precipitated by physical trauma. J Rheumatol. 1990;17(5):695–697
  153. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237:1154–1162
  154. Johansson O, Liang Y. Neurotrophins and their receptors in the skin: a tribute to Rita Levi-Montalcini. Biomed Rev. 1999;10:15–23
  155. Wyatt S, Shooter EM, Davies AM. Expression of the NGF receptor gene in sensory neurons and their cutaneous targets prior to and during innervation. Neuron. 1990;4(3):421–427
  156. Raychaudhuri SP, Jiang WY, Raychaudhuri SK. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol. 2008;172(4):961–971
  157. Fantini F, Magnoni C, Bracci-Laudiero L, Pincelli C. Nerve growth factor is increased in psoriatic skin. J Invest Dermatol. 1995;105:854–855
  158. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149:718–730
  159. Raychaudhuri SP, Jiang W-Y, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Dermatol Venereol. 1998;78:84–86
  160. Raychaudhuri SP, Jiang W-Y, Smoller BR, Farber EM. Nerve growth factor and its receptor system in psoriasis. Br J Dermatol. 2000;143(1):198–200
  161. White B. Immune abnormalities in systemic sclerosis. Clin Dermatol. 1994;12(3):349–359
  162. Matucci-Cerinic M, Kahaleh BM, LeRoy EC. The vascular involvement in systemic scelrosis. In:  Furst D,  Clements P editor. Systemic sclerosis. Philadelphia (PA): Lea and Febiger; 1995;p. 513–574
  163. Strehlow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol. 1998;10(6):572–578
  164. Hawkins RA, Claman HN, Clark RAF, Steigerwald JC. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?. Ann Inter Med. 1985;102(2):182–186
  165. Mican JM, Metcalfe DD. Arthritis and mast cell activation. J Allergy Clin Immunol. 1990;86:677–683
  166. Davies AM, Bandtlow C, Heumann R, Korsching S, Rohrer H, Thoenen H. Timing and site of nerve growth factor synthesis in developing skin in relation to innervation and expression of the receptor. Nature. 1987;326(6111):353–358
  167. Pearce FL, Thompson HL. Some characteristics of histamine secretion from rat peritoneal mast cells stimulated with nerve growth factor. J Physiol. 1986;372:379–393
  168. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, et al. Mast cells synthesize, store and release nerve growth factor. Proc Natl Acad Sci USA. 1994;91(9):3739–3743
  169. Tuveri MA, Passiu G, Mathieu A, Aloe L. Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. Clin Exp Rheumatol. 1993;11:319–322
  170. Kahaleh BM, Matucci-Cerinic M. Raynaud‘s phenomenon and scleroderma (Dysregulated neuroendothelial control of vascular tone). Athritis Rheum. 1995;38(1):1–4
  171. Piga M, Passiu G, Carta P, Satta L, Cherchi V, Pala R, et al. Increased pulmonary epithelial permeability in systemic sclerosis is associated with enhanced cutaneous nerve growth factor expression. Eur J Int Med. 2000;11:156–160
  172. Matucci-Cerinic M, Giacomelli R, Pignone A, Cagnoni ML, Generini S, Casale R, et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis. 2001;60:487–494
  173. Bracci-Laudiero L, Aloe L, Levi-Montalcini R, Galeazzi M, Schilter D, Scully JL, et al. Increased levels of NGF in sera of systemic lupus erythematosus patients. Neuroreport. 1993;4:563–565
  174. Xu Z, Chen Y. Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):360–361
  175. Aalto K, Korhonen L, Lahdenne P, Pelkonen P, Lindholm D. Nerve growth factor in serum of children with systemic lupus erythematosus is correlated with disease activity. Cytokine. 2002;20(3):136–139
  176. Lin CY, Lin CC, Hwang B, Chiang BN. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr. 1993;152(4):309–312
  177. Santambrogio L, Benedetti M, Chao MV, Muzaffar R, Kulig K, Gabellini N, et al. Nerve growth factor production by lymphocytes. J Immunol. 1994;153:4488–4495
  178. Falcini F, Matucci Cerinic M, Ermini M, Generini S, Lombardi A, Pignone A, et al. Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol. 1996;23:1798–1802
  179. Yamamoto M, Ito Y, Mitsuma N, Li M, Hattori N, Sobue G. Pathology-related differential expression regulation of NGF. GDNF, CNTF, and IL-6 mRNAs in human vasculitic neuropathy. Muscle Nerve. 2001;24:830–833
  180. Mitsuma N, Yamamoto M, Jijima M, Hattori N, Ito Y, Tanka F, et al. Wide range of lineages of cells expressing nerve growth factor mRNA in the nerve lesions of patients with vasculitic neuropathy: an implication of endoneurial macrophage for nerve regeneration. Neuroscience. 2004;129(1):109–117
  181. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol. 1987;21(5):431–437
  182. Jansen I, Uddman R, Hocherman M, Ekman R, Jensen K, Olesen J, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol. 1986;20(4):496–501
  183. Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides. 1992;13(3):527–536
  184. Uddman R, Edvinsson L, Jansen I, Stiernholm P, Jensen K, Olesen J, et al. Peptide-containing nerve fibers in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain?. Pain. 1986;27(3):391–399
  185. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia. 1995;15(4):272–276
  186. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56
  187. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16(2):157–168
  188. Anand P, Parrett A, Chadwick L, Hamlyn P. Nerve growth factor concentrations in human cerebral blood vessels. Neurol Neurosurg Psychiatry. 1997;62(2):199–200
  189. Tuttle JB, Etheridge R, Creedon DJ. Receptor-mediated stimulation and inhibition of nerve growth factor secretion by vascular smooth muscle. Exp Cell Res. 1993;208(2):350–361
  190. DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, Schik CM, et al. The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron. 1992;8(5):983–993
  191. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62(2):327–331
  192. Saldanha G, Hongo J, Plant G, Acheson J, Levy I, Anand P. Decreased CGRP, but preserved TrkA immunoreactivity in nerve fibres in inflamed human superficial temporal arteries. J Neurol Neurosurg Psychiatry. 1999;66:390–392
  193. Siminoski K, Murphy RA, Rennert P, Heinrich G. Cortisone, testosterone, and aldosterone reduce levels of nerve growth factor messenger ribonucleic acid in L-929 fibroblasts. Endocrinology. 1987;121(4):1432–1437
  194. Jockers-Scherübl MC, Zouboulis CC, Boegner F, Hellweg R. Is nerve growth factor a serum marker for neurological and psychiatric complications in Behçet's disease?. Lancet. 1996;347:982
  195. Accorinti M, Bruscolini A, Lambiase A, Speranza S, Bonini S, Pivetti-Pezzi P. Nerve growth factor in Behçet's disease. Adv Exp Med Biol. 2003;528:283–285
  196. Müller W, Lautenschläger J. Generalized tendomypathy Il: phatogenesis and therapy. Z Rheumatol. 1990;49:22–29
  197. Seidel MF, Weinreich GF, Stratz T, Müller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int. 2007;27(11):1025–1030
  198. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26:1564–1569
  199. Lautenschläger J, Seglias J, Bruckle W, Müller W. Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol. 1991;10:168–173
  200. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593–1601
  201. Sarcielli P, Mancini ML, Floridi A, Coppola F, Rossi C, Nardi K, et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain. 2007;8(9):737–745
  202. Jackson HC, Winkelmann RK, Bickel WH. Nerve endings in the human lumbar spinal column and related structures. J Bone Joint Surg. 1966;48(7):1272–1281
  203. Malinsky J. The ontogenetic development of nerve terminals in the intervertebral disc of man. Acta Anat. 1959;38:96–113
  204. Yoshizawa H, O'Brien JP, Smith WT, Trumper M. The neuropathology of intervertebral discs removed for low-back pain. J Pathol. 1980;132(2):95–104
  205. Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O'Brien J, Jayson MIV. Nerve ingrowth into the diseased intervertebral disc in chronic back pain. Lancet. 1997;350(9072):178–181
  206. Freemont AJ, Watkins A, Le Maitre C, Baird P, Jeziorska M, Knight MTN, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol. 2002;197:286–292
  207. Seidel MF, März P, Seidel A, Storch M, Späth M, Otten U, et al. Nerve growth factor is increased in the cerebrospinal fluid of patients with spinal nerve compression. Ann Rheum Dis 297;62(1):297.
  208. Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res. 2003;15:364–372
  209. Kikuchi T, Sakuta T, Yamaguchi T. Intra-articular injection of collagenase induces experimental osteoarthritis in mature rabbits. Osteoarthritis Cartilage. 1998;6(3):177–186
  210. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction (Effect of in situ blocking in murine antigen- and zymosan-induced arthritis). Arthritis Rheum. 1995;38(2):164–172
  211. Dicou E, Hurez D, Nerrière V. Natural autoantibodies against nerve growth factor in autoimmune diseases. J Neuroimmunol. 1993;47:159–167
  212. Dicou E, Perrot S, Menkes CJ, Masson C, Nerrière V. Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies. Autoimmunity. 1996;24:1–9
  213. Oppenheim RW. Cell death during development of the nervous system. Ann Rev Neurosci. 1991;14:453–501
  214. Cruwys SC, Garrett NE, Kidd BL. Sensory denervation with capsaicin attenuates inflammation and nociception in arthritic rats. Neurosci Lett. 1995;193(3):205–207
  215. Yamaguchi J, Aihara M, Kobayashi Y, Kambara T, Ikezawa Z. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci. 2009;53(1):48–54
  216. Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R. Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis. Int Arch Allergy Immunol. 2007;144(3):211–216
  217. Mousa SA, Cheppudira BP, Shaqura M, Fischer O, Hofmann J, Hellweg R, et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain. 2007;130(2):502–513
  218. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338(17):1174–1180
  219. Lambiase A, Bonini S, Aloe L, Rama P, Bonini S. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol. 2000;118(10):1446–1449
  220. Aloe L. Nerve growth factor, human skin ulcers and vascularization (Our experience). Prog Brain Res. 2004;146:515–522
  221. Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea. 2006;25(3):352–355
  222. Cellini M, Bendo E, Bravetti G, Campos EC. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res. 2006;38:177–181
  223. Tuveri MA, Generini S, Matucci-Cerinic M, Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet. 2000;356:1739–1740
  224. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol. 2002;50:393–413
  225. Banks BE, Vernon CA, Warner JA. Nerve growth factor has anti-inflammatory activity in the rat hindpaw oedema test. Neurosci Lett. 1984;1(1):47;41-5
  226. Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med. 2000;15(191,10):1799–1806
  227. Flügel A, Matsumuro K, Neumann H, Klinkert WEF, Birnbacher R, Lassmann H, et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol. 2000;31(1):11–12

 The authors have no conflicts of interest to disclose.

PII: S0049-0172(09)00035-3

doi: 10.1016/j.semarthrit.2009.03.002

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 109-126 , October 2010

Article Tools

* Image Usage & Resolution